Figure 3From: Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancerSynergism between PI3K and mTOR inhibition. Cell viability assays in A498 (A) and Caki-2 cells (B): Cells were treated with LY294002 alone, rapamycin alone (at three concentrations) or the combination of LY294002 and rapamycin. The combinations were highly synergistic, with similar viability seen for all three concentrations of rapamycin used. There was no significant difference between the different combination therapies (p > 0.5 for all).Back to article page